Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — J.P. Morgan Healthcare Conference 2024
14 slides from Angiodynamics's conference presentation, Jan 11, 2024
Slide 1: J.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference January 11, 2024 Jim Clemmer, President & CEO
Slide 2: A medical technology platform company
A medical technology platform company focused on a select group of large, high growth markets where meaningful treatment gaps exist in current standard of care. We are transforming our portfolio to be a company focused on investing our resources on innovative technologies backed by science and clini
Slide 3: Cardiovascular disease and cancer have the highest morbidity and mortality worldwide
AngioDynamics Cardiovascular disease and cancer have the highest morbidity and mortality worldwide Global Cardiovascular Disease Burden1 523M diagnosed in 2020 ~19 million deaths Cardiovascular Disease causes 1 in 3 deaths globally Global Cancer Burden2 Cancer causes 1 in 6 deaths globally 19.3M dia
Slide 4: MedTech Markets
MedTech Markets 4 Targeted segments have attractive underpenetrated addressable markets Cardiac Thrombus & Emboli $825M TAM Pulmonary Embolism $2.9B TAM Prostate Cancer $2B TAM Deep Vein Thrombosis $3B TAM Peripheral Arterial Disease $1.1B TAM *AlphaVac PE, Auryon Venous Thrombectomy/DVT, AngioVac L
Slide 5: Med Tech: Invest for Growth
5 AngioDynamics Investments in our Med Tech platforms are funded by operating cash flows from our Med Device portfolio Med Tech: Invest for Growth Disease State Latest Investment Updates Peripheral Arterial Disease Radial length catheter launch Jan 2024 Pathfinder 12 month & 24 month publications Fe
Slide 6: PAD: Auryon Atherectomy System
PAD As of November 2023, the Auryon Atherectomy System has treated over 50,000 patients and reached $100M cumulative sales since its September 2020 launch 6 T H E M A R K E T O U R S O L U T I O N Peripheral Atherectomy Protective of vessel wall c-e Targeted biological reactions to address risk of p
Slide 7: Thrombus Management
Thrombus Management Our differentiated technology platforms offer potential treatment solutions across multiple disease states T H E M A R K E T O U R S O L U T I O N W H Y I T M A T T E R S Only solution on the market with continuous aspiration and simultaneous reinfusion of filtered blood Aspirate
Slide 8: Thrombus Management technology platforms
Thrombus Management All-purpose technology platforms targeted at peripheral and cardiovascular thrombolytic events, including small and large vessels POWERFUL 355 nm laser is designed to deliver an optimized wavelength, pulse width, and amplitude to restore flow in occluded vesselsc, d, g Small Vess
Slide 9: NanoKnife Prostate Initiative
NanoKnife Prostate Initiative* Over 505,000 men with prostate cancer could be treated with this technology 9 USA EMEA APAC LAM CAN *IDE Study in progress; enrollment completed In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in th
Slide 10: International Expansion Plan
International Expansion Plan Expanding our business reach in targeted regions, markets & countries 10 Aligning our Go-to-Market strategy to the different regions, markets & countries, utilizing new partnerships where appropriate to maximize growth Preparing for CE Mark and other selected internation
Slide 11: IDE Clinical Studies and Pathway Expansion
IDE Clinical Studies and Pathway Expansion Corporate Developments – Q2 and YTD FY24 Initiated restructuring of manufacturing footprint to a fully outsourced model Continued portfolio optimization initiatives Full-year adjusted EPS profitability expected in FY27 Cumulative Auryon sales of over $100.0
Slide 12: FY24 Revised Guidance
FY24 Revised Guidance * FY23 pro forma results excluding the divested assets were $306.3 million for revenue, 50.5% for gross margin and adjusted loss per share of $0.43. 12 AngioDynamics Second Quarter FY2024 Earnings Guidance* Revised Guidance* Revenue $328 - $333 million $320 - $325 million Gross
Slide 13: J.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference January 11, 2024 Jim Clemmer, President & CEO
Slide 14: Auryon References
Auryon References Rundback J, Chandra P, Brodmann M, Weinstock B, Sedillo G, Cawich I, et al. Novel laser-based catheter for peripheral atherectomy: 6-month results from the Eximo Medical B-Laser™ IDE study. Catheter Cardiovasc Interv. 2019;1-8. Shammas NW, Chandra P, Brodmann M, Weinstock B, Sedill
AngioDynamics — J.P. Morgan Healthcare Conference 2024 on 6ix